Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer

Nature Communications

Volumn 7, Issue , 2016, Pages

  Lin, Shih Chieh ^a,b   Kao, Chung Yang ^a   Lee, Hui Ju ^a   Creighton, Chad J ^a   Ittmann, Michael M ^a   Tsai, Shaw Jenq ^b   Tsai, Sophia Y ^a   Tsai, Ming Jer ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CENPF PROTEIN; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 2; FOXM1 PROTEIN; MICRORNA; MICRORNA 101; MICRORNA 27A; ORPHAN NUCLEAR RECEPTOR; PROTEIN; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; CENTROMERE PROTEIN F; FORKHEAD BOX PROTEIN M1; FOXM1 PROTEIN, HUMAN; MIRN101 MICRORNA, HUMAN; MIRN27 MICRORNA, HUMAN; NONHISTONE PROTEIN;

CANCER; DATA SET; DRUG RESISTANCE; GENE EXPRESSION; GENETIC MARKER; RNA;

ARTICLE; CELL INVASION; CONTROLLED STUDY; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; PROSTATE CANCER; ANIMAL; GENETICS; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; CHROMOSOMAL PROTEINS, NON-HISTONE; COUP TRANSCRIPTION FACTOR II; FORKHEAD BOX PROTEIN M1; HUMANS; MALE; MICE; MICE, INBRED NOD; MICROFILAMENT PROTEINS; MICRORNAS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 84964644503     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11418     Document Type: Article

References (47)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
2. Eggener, S. E. et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J. Urol. 185, 869-875 (2011).
3. Johansson, J. E. et al. Natural history of early, localized prostate cancer. JAMA 291, 2713-2719 (2004).
4. Karlou, M., Tzelepi, V. & Efstathiou, E. Therapeutic targeting of the prostate cancer microenvironment. Nat. Rev. Urol. 7, 494-509 (2010).
5. Shiozawa, Y. et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 121, 1298-1312 (2011).
6. Zhang, H. et al. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res. 71, 3257-3267 (2011).
7. Lucas, J. M. et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 4, 1310-1325 (2014).
8. Fang, Y. X. & Gao, W. Q. Roles of miRNAs during prostatic tumorigenesis and tumor progression. Oncogene 33, 135-147 (2014).
9. Kao, C. J. et al. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene 33, 2495-2503 (2014).
10. Ru, P. et al. miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol. Cancer Ther. 11, 1166-1173 (2012).
11. Saini, S. et al. Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin. Cancer. Res. 17, 5287-5298 (2011).
12. Tucci, P. et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc. Natl Acad. Sci. USA 109, 15312-15317 (2012).
13. Qin, J. et al. COUP-TFII inhibits TGF-beta-induced growth barrier to promote prostate tumorigenesis. Nature 493, 236-240 (2013).
14. Kalin, T. V. et al. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res. 66, 1712-1720 (2006).
15. Halasi, M. & Gartel, A. L. FOX(M1) news-it is cancer. Mol. Cancer Ther. 12, 245-254 (2013).
16. Koo, C. Y., Muir, K. W. & Lam, E. W. FOXM1: From cancer initiation to progression and treatment. Biochim. Biophys. Acta 1819, 28-37 (2012).
17. Testa, J. R., Zhou, J. Y., Bell, D. W. & Yen, T. J. Chromosomal localization of the genes encoding the kinetochore proteins CENPE and CENPF to human chromosomes 4q24-4q25 and 1q32-4q41, respectively, by fluorescence in situ hybridization. Genomics 23, 691-693 (1994).
18. Laoukili, J. et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat. Cell Biol. 7, 126-136 (2005).
19. Aytes, A. et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25, 638-651 (2014).
20. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
21. Gohji, K. et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int. J. Cancer 79, 96-101 (1998).
22. Moses, M. A. et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 58, 1395-1399 (1998).
23. Nemeth, J. A. et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J. Natl Cancer Inst. 94, 17-25 (2002).
24. Sun, Y. X. et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J. Cell Biochem. 89, 462-473 (2003).
25. Erler, J. T. et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440, 1222-1226 (2006).
26. Payne, S. L., Hendrix, M. J. & Kirschmann, D. A. Paradoxical roles for lysyl oxidases in cancer-a prospect. J. Cell Biochem. 101, 1338-1354 (2007).
27. Erler, J. T. et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15, 35-44 (2009).
28. Kim, W. & Ryan, C. J. Androgen receptor directed therapies in castration-resistant metastatic prostate cancer. Curr. Treat. Options Oncol. 13, 189-200 (2012).
29. Yallapu, M. M. et al. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials 35, 8635-8648 (2014).
30. Gaur, S. et al. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget 6, 29161-29177 (2015).
31. Zhang, T., Xue, X., He, D. & Hsieh, J. T. A prostate cancer-targeted polyarginine-disulfide linked PEI nanocarrier for delivery of microRNA. Cancer Lett. 365, 156-165 (2015).
32. Ambs, S. et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 68, 6162-6170 (2008).
33. Ozen, M., Creighton, C. J., Ozdemir, M. & Ittmann, M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27, 1788-1793 (2008).
34. Coppola, V., De Maria, R. & Bonci, D. MicroRNAs and prostate cancer. Endocr. Relat. Cancer 17, F1-17 (2010).
35. Boll, K. et al. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 32, 277-285 (2013).
36. Zadran, S., Remacle, F. & Levine, R. D. miRNA and mRNA cancer signatures determined by analysis of expression levels in large cohorts of patients. Proc. Natl Acad. Sci. USA 110, 19160-19165 (2013).
37. Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423-1437 (2013).
38. Balli, D. et al. Foxm1 transcription factor is required for lung fibrosis and epithelial-to-mesenchymal transition. EMBO J. 32, 231-244 (2013).
39. Bao, B. et al. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J. Cell. Biochem. 112, 2296-2306 (2011).
40. Bubendorf, L. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31, 578-583 (2000).
41. Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197 (2012).
42. Fizazi, K. et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol. 15, 1147-1156 (2014).
43. Korpal, M. et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 3, 1030-1043 (2013).
44. Arora, V. K. et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155, 1309-1322 (2013).
45. Lin, S. C. et al. Suppression of COUP-TFII by proinflammatory cytokines contributes to the pathogenesis of endometriosis. J. Clin. Endocrinol. Metab. 99, E427-E437 (2014).
46. Creighton, C. J. et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J. Clin. Oncol. 26, 4078-4085 (2008).
47. Creighton, C. J. et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl Acad. Sci. USA 106, 13820-13825 (2009).